glp-1 and autoimmune disease Association between diseases glucagon-like peptide-1 receptor agonists: A real-world evidence study Roles of glucagon-like peptide 1
Description
Hodson, D

The medication's use for weight management in competitive sports may raise ethical questions separate from formal prohibition

Phase 2 data published in the New England Journal of Medicine showed mean body weight reductions of up to 24.2% at the highest dose tested over 48 weeks [8]

Furthermore, the study found no increased risk of hospitalization for side effects like diabetic ketoacidosis or severe hypoglycemia, suggesting that GLP-1RAs may represent a promising adjunctive therapy warranting further study in T1D management
Novo Nordisk launched its oral obesity med on Jan

4U per week
